PA8471001A1 - Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado - Google Patents

Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado

Info

Publication number
PA8471001A1
PA8471001A1 PA19998471001A PA8471001A PA8471001A1 PA 8471001 A1 PA8471001 A1 PA 8471001A1 PA 19998471001 A PA19998471001 A PA 19998471001A PA 8471001 A PA8471001 A PA 8471001A PA 8471001 A1 PA8471001 A1 PA 8471001A1
Authority
PA
Panama
Prior art keywords
bis
quinazolinamine
metoxyetoxy
mesylate
ethylphenylamine
Prior art date
Application number
PA19998471001A
Other languages
English (en)
Inventor
Timothy Norris
Douglas John Meldrum Allen
Ravi Mysore Shanker
Jeffrey William Raggon
Dinos Paul Santafianos
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of PA8471001A1 publication Critical patent/PA8471001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LAS FORMAS ANHIDRAS E HIDRATADAS DEL MESILATO DE N-(3-ETINILFENIL)-6,7-BIS-(2-METOXIETOXI)-4-QUINAZOLINAMINA. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN MESILATO DE N-(3- ETINILFENIL)-6,7-BIS-(2-METOXIETOXI)-4-QUINAZOLINAMINA Y A PROCEDIMIENTOS DE TRATAMIENTO DE ALTERACIONES HIPERPROLIFERATIVAS, COMO EL CANCER, MEDIANTE ADMINISTRACION DE MESILATO DE N-(3-ETINILFENIL)-6,7-BIS-(2-METOXIETOXI)-4-QUINAZOLINAMINA.
PA19998471001A 1998-04-29 1999-04-27 Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado PA8471001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (1)

Publication Number Publication Date
PA8471001A1 true PA8471001A1 (es) 2000-09-29

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998471001A PA8471001A1 (es) 1998-04-29 1999-04-27 Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado

Country Status (42)

Country Link
EP (1) EP1076652B1 (es)
JP (1) JP4652569B2 (es)
KR (1) KR100668412B1 (es)
CN (2) CN101219999A (es)
AP (1) AP1252A (es)
AR (1) AR018201A1 (es)
AT (1) ATE295839T1 (es)
AU (1) AU759691C (es)
BR (1) BR9910025A (es)
CA (1) CA2330447C (es)
CO (1) CO5060467A1 (es)
CZ (1) CZ298230B6 (es)
DE (1) DE69925366T2 (es)
DZ (1) DZ2777A1 (es)
EA (1) EA002836B1 (es)
EG (1) EG24000A (es)
ES (1) ES2238825T3 (es)
GT (1) GT199900063A (es)
HK (1) HK1037180A1 (es)
HN (1) HN1999000057A (es)
HU (1) HU227569B1 (es)
ID (1) ID27198A (es)
IL (1) IL139172A0 (es)
MA (1) MA26624A1 (es)
ME (1) MEP42008A (es)
MX (1) MXPA00010610A (es)
MY (1) MY136033A (es)
NO (1) NO317301B1 (es)
NZ (1) NZ508154A (es)
OA (1) OA11769A (es)
PA (1) PA8471001A1 (es)
PE (1) PE20000441A1 (es)
PL (1) PL196940B1 (es)
RS (1) RS50081B (es)
SA (1) SA99200216B1 (es)
TN (1) TNSN99079A1 (es)
TR (1) TR200003166T2 (es)
TW (1) TWI248437B (es)
UA (1) UA60363C2 (es)
UY (1) UY26099A1 (es)
WO (1) WO1999055683A1 (es)
ZA (1) ZA992972B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JP4724657B2 (ja) 2003-05-30 2011-07-13 アストラゼネカ ユーケー リミテッド プロセス
ATE373661T1 (de) 2003-06-10 2007-10-15 Hoffmann La Roche 1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005107747A2 (en) 2004-05-06 2005-11-17 Bioresponse, Llc Diindolymethane formulations for the treatment of leiomyomas
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
KR20140069232A (ko) * 2007-04-04 2014-06-09 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
ES2492645T3 (es) 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
EP2176241B1 (en) 2007-08-17 2015-12-23 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
ATE446955T1 (de) * 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
CZ20003974A3 (en) 2001-05-16
KR100668412B1 (ko) 2007-01-12
HU227569B1 (en) 2011-08-29
AP1252A (en) 2004-02-25
EG24000A (en) 2008-03-19
BR9910025A (pt) 2000-12-26
CN101219999A (zh) 2008-07-16
HN1999000057A (es) 1999-09-29
EA200001112A1 (ru) 2001-04-23
CN1298396A (zh) 2001-06-06
AU2850999A (en) 1999-11-16
EA002836B1 (ru) 2002-10-31
HUP0101818A1 (hu) 2002-03-28
MEP42008A (en) 2011-02-10
CA2330447A1 (en) 1999-11-04
TNSN99079A1 (fr) 2005-11-10
EP1076652A1 (en) 2001-02-21
NO20005453L (no) 2000-12-20
SA99200216B1 (ar) 2006-06-04
TWI248437B (en) 2006-02-01
CA2330447C (en) 2009-06-30
NO20005453D0 (no) 2000-10-27
AU759691B2 (en) 2003-04-17
KR20010078710A (ko) 2001-08-21
ID27198A (id) 2001-03-08
ATE295839T1 (de) 2005-06-15
EP1076652B1 (en) 2005-05-18
MY136033A (en) 2008-07-31
PL196940B1 (pl) 2008-02-29
JP4652569B2 (ja) 2011-03-16
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
ZA992972B (en) 2000-10-30
RS50081B (sr) 2009-01-22
TR200003166T2 (tr) 2001-02-21
JP2002513009A (ja) 2002-05-08
HUP0101818A3 (en) 2002-05-28
OA11769A (en) 2005-07-25
AP9901523A0 (en) 1999-06-30
AU759691C (en) 2004-04-29
DE69925366D1 (de) 2005-06-23
MA26624A1 (fr) 2004-12-20
CO5060467A1 (es) 2001-07-30
GT199900063A (es) 2000-10-20
MXPA00010610A (es) 2002-07-02
ES2238825T3 (es) 2005-09-01
HK1037180A1 (en) 2002-02-01
IL139172A0 (en) 2001-11-25
UA60363C2 (uk) 2003-10-15
PL343766A1 (en) 2001-09-10
AR018201A1 (es) 2001-10-31
NO317301B1 (no) 2004-10-04
CZ298230B6 (cs) 2007-08-01
PE20000441A1 (es) 2000-05-23
WO1999055683A1 (en) 1999-11-04
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
NZ508154A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
PA8471001A1 (es) Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
CY1106405T1 (el) Παραγωγα κουιναζολινης
GT200000014A (es) Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
PA8583301A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
PA8531401A1 (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas
PA8583201A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
PA8623001A1 (es) Compuestos de quinolina sustituidos
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
TR200200768T2 (tr) Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
BR0211905A (pt) Dialdeìdos de rapamicina
PA8548401A1 (es) Agentes antibacterianos
HN2002000300A (es) Nuevos derivados de piperazina
ATE509004T1 (de) 3-alkylierte 5,5',6,6',7,7',8,8'-octahydro-2, 2'binaphthole und 3,3'-dialkylierte 5,5',6,6',7, 7',8,8'-octahydro-2,2'-binaphthole sowie herstellungsverfahren dafür
SV2004001367A (es) Compuestos y procedimientos antitumorales ref.x-15365
BR0209440A (pt) Sulfonamidas
PA8553701A1 (es) Agentes antidiabeticos
PT1028950E (pt) Quinazolina-2,4-dionas 7-substituidas uteis como agentes antibacterianos
ATE497967T1 (de) Interzelluläre kommunikation erleichternden verbindungen und deren medizinischen verwendungen
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
ECSP992936A (es) Mesilato de n-(3- etinilfenilamino) -6,7- bis (2- metoxietoxi) -4- quinazolinamina anhidro y monohidratado
BR0308201A (pt) Derivados de quinolina